Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study

Indian Journal of Medical Research

Volumn 136, Issue 1, 2012, Pages 46-53

  Viswanathan, Vijay ^a   Tilak, Priyanka ^a   Kumpatla, Satyavani ^a  

^a MV Hospital for Diabetes   (India)

Author keywords

Diabetic nephropathy; Indians; Macroalbuminuria; Proteinuria; Risk factors; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; CREATININE; HEMOGLOBIN A1C; INSULIN; TRIACYLGLYCEROL; UREA;

ADULT; ALBUMINURIA; ANTHROPOMETRY; ARTICLE; BIOCHEMISTRY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PROTEINURIA; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL;

AGE FACTORS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LONGITUDINAL STUDIES; PROTEINURIA; REGRESSION ANALYSIS; RISK FACTORS; TIME FACTORS; TRIGLYCERIDES; UREA;

EID: 84865453095     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Brancati FL, Whelton PK, Randall BL Neaton JD, Stamler J, Klag MJ. Risk of end stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. JAMA 1997; 278: 2069-2074.
2. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year follow up study. BMJ 1996; 313: 779-784.
3. Parving HH, Mauer M, Ritz E. Diabetic nephropathy: In: Brenner BM, editor. Brenner & Rector's The kidney, 7th ed. vol. 2. Philadelphia: Sauders; 2004, p. 1777-17818.
4. Jia W, Gao X, Pang C, Hou X, Bao Y, Liu W. Prevalenceand risk factors of albuminuria and chronic kidney disease in Chinese population with type 2 diabetes and impaired glucose regulation: Changhai diabetic complications study (SHDCS). Neph Dialy Transp 2009; 24: 3724-3731.
5. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin dependent diabetes mellitus. Lancet 1982; 1: 1430-1432.
6. Deckert T, Yokoyama H, Mathiesen ER, Ronn B, Jensen T, Feldt-Rasmussen B. Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. BMJ 1996; 312: 871-874.
7. Unnikrishnan R, Rema M, Pradeepa R, Deepa M. Prevalenceand risk factors of diabetic nephropathy in an urban south Indian population. Diabetes Care 2007; 30: 2019-2024.
8. Schmitz A, Vaeth M. Microalbuminuria: A major risk factor innon insulin dependent diabetes. A 10 year follow up study of 503 patients. Diabet Med 1988; 5: 126-134.
9. Chandie Shaw PK, Vandendroucke JP, Tjandra YI, Rosendaal FR, Rosman JB, Geerlings W, et al. Increased end-stage diabetic nephropathy in Indo-Asian immigrants living in the Netherlands. Diabetologia 2002; 45: 337-341.
10. Burden AC, McNally PG, Feehally J Walls J. Increased incidence of end-stage renal failure secondary to diabetes mellitus in Asian ethnic groups in United Kingdom. Diabet Med 1992; 9: 641-645.
11. Microalbuminuria Collaborative study Group UK. Microalbuminuria in type 1 (insulin-dependent) diabetic patients: prevalence and clinical characteristics. Diabetes Care 1992; 15: 495-15501.
12. Wiseman MJ, Viberti GC, Mackintosh D, Jarrett RJ, Keen H. Glycaemia, arterial pressure and microalbuminuria in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1984; 26: 402-405.
13. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study. Lancet 1999; 353: 617-622.
14. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving H. Randomized, controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. BMJ 1999; 319: 24-25.
15. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; For the collaborative study group. The effect of angiotensin converting enzyme inhibitor on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
16. The Microalbuminuria Collaborative Study Group, UK. Predictors of the development of microalbuminuria in patients with type 1 diabetes mellitus: a seven year prospective study. Diabet Med 1999; 16: 918-925.
17. Rossing P, Hougaard P, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients. Diabetes Care 2002; 25: 859-864.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-34.
19. Gall MA, Hougaard P, Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non insulin dependent diabetes mellitus: prospective, observational study. BMJ 1997; 314: 783-788.
20. The Diabetes Control and Complications Trial Research Group. The effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complication trial. Kidney Int 1995; 47: 1703-1720.
21. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
22. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an update meta analysis. Nephrol Dial Transplant 1995; 10: 39-45.
23. Peterson JC, Alder S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, et al. Blood pressure control, proteinuria and the progression of renal disease: the Modification of Diet in Renal Disease study. Ann Intern Med 1995; 123: 754-762.
24. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on thedevelopment and progression of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.